Adjuvant trastuzumab for breast cancer: Assessing HER2/neu status incurs more costs for treatment

BMJ

Volumn 331, Issue 7526, 2005, Pages 1202-

  Kell, Malcolm R ^a   Power, Colm P ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; GENETICS; HUMAN; NOTE; PROTO ONCOGENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, ERBB-2; HUMANS;

EID: 29744468690     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.331.7526.1202     Document Type: Letter

References (3)

1. Dent R, Clemons M. Adjuvant trastuzumab for breast cancer. BMJ 2005; 331: 1035–6. (5 November.)
2. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307 325.
3. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005; 11: 6598 6607.